<DOC>
	<DOC>NCT02731911</DOC>
	<brief_summary>This prospective study will assess Ozurdex in the treatment of Diabetic Macular Oedema in clinical practice.</brief_summary>
	<brief_title>Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pseudophakic or phakic and scheduled for a cataract operation Macular oedema due to DME Previous Ozurdex® treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>